WebClinical trial for Non Cystic Fibrosis Bronchiectasis , Roflumilast in Non-CF Bronchiectasis Study (2024) Overview; Search; Volunteer; ... This is a single-arm, open label, Phase II study of 12-week use of Roflumilast in stable-state non-cystic fibrosis bronchiectasis subjects. ... WebThis indicates a possible anti-inflammatory effect of roflumilast in non-CF bronchiectasis with just 4 weeks of treatment, though this pilot was meant for feasibility study and not powered to detect significant change. The true benefit will likely require a longer duration of treatment (thus proposing 12 weeks in this study) with sufficient ...

Roflumilast in Non-CF Bronchiectasis Study (2024)

WebRoflumilast has anti-inflammatory actions via decreased neutrophilic airway inflammation. The effectiveness of roflumilast to reduce bronchiectasis exacerbation has never been evaluated. Methods We conducted a double-blinded, randomized, placebo-controlled trial. WebIndeed, bronchiectasis has been reported in 29–57% of patients with COPD, and the presence of bronchiectasis is associated with frequent exacerbations, COPD severity, and even increased mortality. 14–17 COPD is also a common comorbidity in patients with bronchiectasis, reporting up to 58% of prevalence of COPD diagnosis in patients with … ouhsc andrews academic tower

Roflumilast: MedlinePlus Drug Information

Web22 Jun 2024 · Chronic obstructive pulmonary disease (COPD) is the third leading cause of death in the world [].The symptoms include dyspnea, cough and sputum production and worsen during exacerbations of COPD, which are associated with accelerated mortality [].To reduce the symptoms and the exacerbation, single or dual inhaled bronchodilators are … WebThe potential benefit of roflumilast for treating COPD with bronchiectasis has to be further investigated. Asthma-COPD overlap syndrome (ACOS) is generally observed in 15–20% of patients in airway disease clinics, and they experience more frequent exacerbation and account for greater health care cost utilization than those with pure COPD ( 73 , 74 ). Web3 Aug 2024 · Roflumilast has anti-inflammatory actions via decreased neutrophilic airway inflammation. The effectiveness of roflumilast to reduce bronchiectasis exacerbation has never been evaluated.... rodolphe remark